# US 2025/0367296 A1 · Viscosity-reducing excipient composition and low-viscosity highly concentrated protein formulation containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367296 A1
- Document ID: US20250367296A1
- Status: Published application
- Kind: A1
- Application number: 18/870,745
- Filed: 2023-05-22
- Published: 2025-12-04
- Earliest claimed: 2022-06-03
- Assignees: Green Cross Holdings Corporation
- Applicants: Green Cross Holdings Corporation
- Inventors: Haeng Eun SONG; Jae Woon SON; Jong Moon SON
- Web page: https://patentgrep.com/patent/US20250367296A1

## CPC

- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- C07K 16/06: from serum
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are an excipient composition for reducing the viscosity of protein pharmaceuticals and a low-viscosity, high-concentration protein composition formulation containing the same which have a remarkably low viscosity at a high protein concentration of about 20% or more, are convenient to manufacture, store, and use, and are particularly useful for the preparation of injections for antibody treatment for subcutaneous administration and intramuscular administration. In particular, the high-concentration protein formulation can be advantageously used immediately after storage without separate preheating because it maintains low viscosity even when stored at low temperature.

## Claims

### Claim 1

A pharmaceutical composition comprising:
at least one protein;
glycine or proline;
benzenesulfonic acid; and camphorsulfonic acid.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the protein is an antibody or an antigen-binding fragment thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the protein is comprised at a concentration of 10% to 25% (w/v).

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the glycine or protein is comprised at a concentration of 150 mM to 250 mM.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the benzenesulfonic acid and the camphorsulfonic acid are each independently comprised at a concentration of 10 mg/mL to 27.5 mg/mL.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein a total concentration of the benzenesulfonic acid and the camphorsulfonic acid is 20 mg/mL to 50 mg/mL.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the benzenesulfonic acid and the camphorsulfonic acid are comprised in a weight ratio of 1:0.5 to 1:2.5.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition has an absolute viscosity of less than 25 cP at 4° C.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The pharmaceutical composition according to any one of claims 1 to 8, wherein the pharmaceutical composition is administered by subcutaneous injection.

### Claim 10

A method of reducing a viscosity of a composition containing protein, the method comprising adding a benzenesulfonic acid and camphorsulfonic acid as a viscosity-reducing excipient to a composition containing at least one protein, and glycine or proline.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the protein is an antibody or an antigen-binding fragment thereof.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the protein is comprised at a concentration of 10% to 25% (w/v).

### Claim 13 (depends on 9)

The method according to claim 9, wherein the glycine or protein is comprised at a concentration of 150 mM to 250 mM.

### Claim 14 (depends on 9)

The method according to claim 9, wherein a total concentration of the benzenesulfonic acid and the camphorsulfonic acid is 20 mg/mL to 50 mg/mL.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the benzenesulfonic acid and the camphorsulfonic acid are comprised in a weight ratio of 1:0.5 to 1:2.5.
